BMS-345541: Selective IKK-1/IKK-2 Inhibitor for NF-κB Pathway Modulation

Executive Summary: BMS-345541 (free base) is a highly selective allosteric inhibitor of IκB kinases IKK-1 and IKK-2, which are pivotal in cytokine-induced NF-κB pathway activation (https://www.apexbt.com/bms-345541-free-base.html). It demonstrates IC₅₀ values of 4 μM (IKK-1) and 0.3 μM (IKK-2) under defined in vitro conditions, with robust effects on cytokine suppression in THP-1 monocytes and in vivo murine models (https://doi.org/10.3892/ijmm.2020.4701). BMS-345541 is insoluble in water but dissolves at ≥70 mg/mL in DMSO and ≥2.49 mg/mL in ethanol with gentle warming and ultrasonic treatment. In models of inflammation, angiogenesis, and cancer cell apoptosis, BMS-345541 serves as a critical tool for dissecting the IKK-NF-κB signaling axis. The compound's specificity, storage, and handling requirements are well characterized for reproducible laboratory use.

Biological Rationale

The NF-κB pathway regulates genes involved in immunity, inflammation, cell survival, and angiogenesis. Dysregulation of NF-κB is implicated in chronic inflammatory diseases, cancer, and vascular disorders (https://doi.org/10.3892/ijmm.2020.4701). Cytokine-induced activation of IκB kinases (IKK-1/IKK-2) leads to phosphorylation and degradation of IκB, freeing NF-κB to translocate to the nucleus and drive transcription of inflammatory and survival genes. Inhibition of the IKK complex is a validated strategy to block NF-κB signaling and downstream pathological processes. BMS-345541 enables precise pharmacological interrogation of this pathway in diverse experimental models.

Mechanism of Action of BMS-345541 (free base)

BMS-345541 is a small molecule that selectively binds to an allosteric site on IKK-1 and IKK-2, inhibiting their kinase activity (https://www.apexbt.com/bms-345541-free-base.html). The IC₅₀ for IKK-2 is approximately 0.3 μM, and for IKK-1 is 4 μM, measured by enzyme inhibition assays. This selectivity allows for targeted suppression of cytokine-induced NF-κB activation without affecting unrelated kinases. In cellular assays, BMS-345541 blocks IKK phosphorylation events, preventing IκB degradation and subsequent NF-κB nuclear translocation. This results in reduced transcription of pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6, IL-8) and modulation of apoptosis pathways. In animal models, BMS-345541 dose-dependently inhibits LPS-induced TNF production, confirming its mechanistic effect in vivo (https://doi.org/10.3892/ijmm.2020.4701).

Evidence & Benchmarks

• BMS-345541 inhibits IKK-2 with an IC₅₀ of 0.3 μM and IKK-1 with an IC₅₀ of 4 μM in kinase assays (https://www.apexbt.com/bms-345541-free-base.html).
• In THP-1 monocytes, BMS-345541 suppresses cytokine-induced phosphorylation of IKK and blocks NF-κB-dependent transcription (https://doi.org/10.3892/ijmm.2020.4701).
• Pretreatment with BMS-345541 reduces production of TNF-α, IL-1β, IL-6, and IL-8 in cytokine-stimulated monocytes (https://doi.org/10.3892/ijmm.2020.4701).
• In glioma and melanoma cell lines, BMS-345541 inhibits proliferation and induces apoptosis, as measured by cell viability and apoptotic markers (https://www.apexbt.com/bms-345541-free-base.html).
• In BALB/c mice, intraperitoneal administration of BMS-345541 (dose: 100 mg/kg) nearly abolishes LPS-induced serum TNF production (https://doi.org/10.3892/ijmm.2020.4701).
• BMS-345541 at concentrations of 1–100 μM produces measurable effects within 1 hour in cellular assays (https://www.apexbt.com/bms-345541-free-base.html).
• BMS-345541's effects on angiogenesis and inflammation were benchmarked in critical limb ischemia mouse models, where it reversed pro-angiogenic actions of thymosin-β4 via NF-κB pathway inhibition (https://doi.org/10.3892/ijmm.2020.4701).

This article extends the mechanistic discussion from 'Precision Inhibition of IKK-NF-κB Signaling: Strategic Guidance' by offering experimental benchmarks and clarifying solubility/handling parameters for BMS-345541. For advanced translational context, see 'Unraveling the Therapeutic Potential of IKK-NF-κB Pathway Inhibition', which this article updates with new in vivo angiogenesis findings. Finally, for a comparative analysis of pathway modulation agents, consult 'Advanced Insights into NF-κB Pathway Modulation'.

Applications, Limits & Misconceptions

BMS-345541 (free base) is a validated tool for dissecting the IKK-NF-κB signaling pathway in studies of inflammation, immune response, cancer cell apoptosis, and angiogenesis. It enables mechanistic studies in both cell culture and animal models, facilitating translational research in disease mechanisms involving cytokine-induced NF-κB activation. However, boundaries of its application must be clearly defined.

Common Pitfalls or Misconceptions

• BMS-345541 is not a pan-kinase inhibitor; its activity is selective for IKK-1/IKK-2 and does not extend to unrelated kinases.
• The compound is insoluble in water; attempts to dissolve in aqueous buffers may lead to precipitation and inconsistent dosing.
• BMS-345541 does not directly inhibit NF-κB DNA binding but acts upstream at the level of IKK inhibition.
• Prolonged storage of prepared solutions, especially at temperatures above -20°C, can lead to compound degradation and loss of activity.
• In vivo effects may differ by species, tissue type, and induction model; dosing must be empirically validated for each application.

Workflow Integration & Parameters

BMS-345541 should be handled as per manufacturer guidelines. Store powder at -20°C in a dry environment. For stock solutions, dissolve in DMSO (≥70 mg/mL) or ethanol (≥2.49 mg/mL) with gentle warming and ultrasonic treatment. Prepare working concentrations freshly; avoid long-term storage of solutions. In cell-based assays, use a concentration range of 1–100 μM, with typical incubation times of 1 hour. In animal studies, dosing regimens up to 100 mg/kg (intraperitoneal) have shown efficacy in inhibiting LPS-induced TNF production in mice. Always verify solubility and stability for your specific assay conditions. For more product details, refer to the BMS-345541 (free base) product page.

Conclusion & Outlook

BMS-345541 (free base) is a benchmark IKK-1/IKK-2 inhibitor, supporting rigorous investigation of the NF-κB pathway in inflammation, cancer, and vascular disease models. Its selectivity, defined handling parameters, and reproducible biological effects make it indispensable for hypothesis-driven translational research. Ongoing studies continue to clarify the therapeutic potential and mechanistic boundaries of IKK-NF-κB pathway inhibition in complex disease states.